Beacon Biosignals
Beacon Biosignals records and analyzes brain activity for sleep diagnostics and drug development. Its Waveband, the former Dreem 3S, is a prescription EEG headband that records at home or in the clinic and uses machine learning to stage sleep, and the Beacon Pal app sends recordings to the Beacon Datastore, where research teams analyze cohorts, combine sources and pull datasets through Beacon HQ. SleepStageML is separate FDA cleared software that scores overnight sleep laboratory recordings in adults and returns the original EEG with automated annotations for a clinician to review. A multicenter study in Sleep compared Waveband's staging with expert scoring of polysomnography in adults with insomnia symptoms.
For drug developers Beacon runs device logistics, site training, data quality review and scientific support, and it has supported more than 40 clinical trials and analyzed more than 2 million hours of EEG. Takeda works with it on sleep disorder trials, Harmony Biosciences on hypersomnia endpoints and Syndeio on depression biomarkers. Since folding CleveMed into the Beacon brand in June 2026, it also sells the SleepView Monitor, a Type III home sleep test, and the mail order SleepView Direct service, with more than 500,000 home tests completed.
Jacob Donoghue and Jarrett Revels founded the Boston company, which raised a $97 million Series B after an extension in April 2026. In October 2026 it acquired Snap Diagnostics, a home sleep testing provider in all 50 states that keeps its own name, and it plans a wider EEG enabled home testing rollout from 2027.
Capability Axes
An AI Health Index grade measures what a buyer can verify from public sources on the date shown. It is not a rating of how good the product is. A vendor can build an excellent system and grade low on an axis because it publishes nothing an outsider can check. How grades read
Learned analysis is what turns raw brain signals into usable results. Waveband measures EEG directly and stages sleep with machine learning, SleepStageML applies a trained classifier to overnight laboratory recordings, and the Datastore supports quantitative EEG features that can serve as trial endpoints or define patient groups.
Collection hardware, transfer, study management and clinical review surround that core. The home sleep testing line acquired with CleveMed, the SleepView Monitor and SleepView Direct, is described in terms of automated screening and workflow rather than learned scoring, so the AI weight sits with the EEG products and the trial analytics rather than with every test Beacon ships.
SleepStageML scores each segment automatically and returns the original signals with stage annotations for a qualified clinician to review before clinical use, in their own viewing software if they prefer. Report Studio supports manual scoring under its own clearance, and SleepView Direct offers optional manual scoring by a registered polysomnographic technologist on its Gold plan.
In studies, Beacon's team reviews data quality and compliance while sponsors monitor sites and examine outliers in the portal. Research teams and clinicians interpret the results, and automated scoring is kept distinct from the clinical evaluation of the patient.
SleepStageML is a convolutional neural network trained on sleep laboratory recordings with human stage labels. It scores five stages from EEG channels only, leaving the other polysomnography channels out of its inputs, and the filing describes the validation population, the comparison with a technologist consensus and several known limitations. The Waveband evaluation describes a separate implementation built on the headband's own sensor signals.
Network parameters, a reproducible training recipe and the full training datasets are proprietary, and Beacon describes its wider aim as building the largest clinically validated neurophysiology dataset.
The models are Beacon's own. It developed SleepStageML and submitted it to the FDA under its name, trained on labeled polysomnography from a range of sources, and the Waveband headband came with the Dreem research business it acquired in 2023. Development draws on its own EEG recording database and on clinical study data gathered with sponsors and research sites.
That keeps the chain from recording to stage score short. A full inventory of external components, software dependencies and the operating version of each analytics module is not published, and the staging software is kept distinct from the hardware and research portal.
A multicenter study in Sleep tested Waveband against laboratory polysomnography in adults with insomnia symptoms. Of 44 participants, 38 nights remained after exclusions for poor signal quality or fit, and average agreement with the expert consensus was 87.3%, against 85.9% for individual experts measured by the same leave one out method. The device was evaluated in a laboratory setup rather than at home.
The FDA summary for SleepStageML separately reports 84.02% agreement across consensus stages in 100 recordings, with lower agreement for the light N1 stage. SleepView's home testing workflow rests on studies with Cleveland Clinic and Johns Hopkins Hospital.
During a Waveband recording the headband sends signals to Beacon Pal over Bluetooth and encrypts any readings it holds when the connection drops. The Datastore can join separately held data through tokens, and a quality management system governs traceability, backups and retention for trial data. The clinical service privacy policy covers uploads, annotations, reporting and clinical trial consent, and SleepStageML returns the original EEG beside its annotations for human review.
How far recordings are used for secondary model training, and whether customers can set deletion and retention separately for each service, are not stated, which matters for a company building a large neurophysiology dataset.
The service privacy policy covers clinical uploads, annotations, review and reporting. It addresses information entered for clinical trials, including studies involving minors with appropriate authorization, and explains how data subject requests are handled, and the study service adds tokenization and a quality management system for clinical data.
Beacon's business associate role is not stated for each workflow, no agreement is posted, and the service tiers and subcontractors it would cover are not named. That gap widens with the home sleep testing line, where providers send patient orders for diagnosis. Snap Diagnostics operates separately as an independent diagnostic testing facility.
SOC 2 Type 2 is listed for the Datastore, and Beacon participates in the US Data Privacy Framework. The study service describes backups across regions and retention policies tied to Good Clinical Practice, and Waveband documentation covers account provisioning and encryption of EEG signals held on the device during connectivity gaps.
These disclosures cover particular parts of the service, with the quality management system governing the Datastore. The current SOC 2 report and its system boundaries are not available publicly, and nothing shows that the attestation extends to the SleepView home testing line or to Snap Diagnostics.
FDA cleared SleepStageML under K233438 for scoring attended level 1 polysomnography recordings in adults, with qualified clinical review. Waveband, first marketed as Dreem 3S, is a distinct EEG sleep device with clearances K223539 and K242094, the latter for prescription use at home or in healthcare settings. Report Studio, K261747, is cleared for display, review and manual scoring of sleep study data, and the SleepView Monitor is an FDA cleared Type III home sleep test.
Each clearance covers its own device and indication. The trial analytics, and the planned pairing of Snap's services with Waveband, do not inherit an indication from them.
The SleepStageML submission set acceptance criteria before its comparison, pooled agreement for each sleep stage, and states that development recordings came from several clinical sites and a range of patient demographics. The FDA record lists an authorized predetermined change control plan, which governs how the model can be updated. The Waveband publication reports performance by stage, describes the recordings it excluded and documents its small cohort.
Agreement broken down by age, sex, race or ethnicity is not available for routine clinical use of either product, so how staging accuracy varies across patient groups outside the study populations is unknown.
A clinician gets the input recording beside the automated annotation, so any result can be checked and rescored. The SleepStageML dossier reports agreement for each stage against a consensus of three trained sleep technologists across 100 subjects, with confidence intervals, which tells a lab how often to expect disagreement. Technical support takes tickets and calls about recordings or hardware, and study customers have ongoing help with data quality problems.
No accuracy warranty, indemnity for reliance on automated staging or compensation for a delayed resolution of a disputed result appears in the public commercial material.
Sleep labs submit polysomnography recordings in European Data Format and get the signals back with stage annotations in EDF+. The Datastore joins outside data with Beacon data, supports integrations triggered by incoming events and lets study teams download data for analysis or regulatory submissions. SleepView Direct accepts orders from an existing EMR or practice workflow.
That exchange serves research systems and signal review. No named electronic health record connection sends orders in or returns results into a live chart, and the order path from an EMR is described as a workflow rather than a named interface.
Waveband streams recordings into a mobile app, which uploads them to the Datastore that Beacon manages. Trial teams work in the Beacon HQ portal, laboratory recordings for SleepStageML arrive by secure file transfer, and SleepView providers use a web portal that runs in Edge or Chrome. Automated backups run across regions, and the company participates in the EU and US Data Privacy Framework for international transfers.
The primary and backup storage regions for each customer are not specified, no choice of cloud region is offered, and no customer hosted Datastore is described. The headband keeps encrypted recordings temporarily when it cannot reach the phone.
Life sciences sponsors, sleep clinicians and academic customers each have their own contact route. The trial offering bundles device provisioning, setup, data monitoring, training, analytics access and scientific services, and the headband is not sold to consumers. SleepView Direct comes in Gold and Silver plans that both include the monitor, web portal, shipping and disposables, with manual scoring on Gold, and Beacon supports providers with CPT coding and billing.
No device price, software seat rate, per subject trial price or SleepView plan price is published. Snap bills insurers for its own testing, which says nothing about the cost of the research platform.
Waveband records sleep at home and in clinics. The insomnia study tested it against laboratory polysomnography, Harmony Biosciences uses the headband and algorithms over consecutive nights at home in hypersomnia research, Takeda runs sleep disorder trials with Beacon, and Syndeio works with it on EEG biomarkers in major depressive disorder. Beacon describes its trial support as spanning Phase 1 to 4, and an October 2026 partnership with Project Sleep targets faster diagnosis of idiopathic hypersomnia and narcolepsy.
SleepStageML's clearance covers adult laboratory recordings only. The SleepView line serves sleep centers and providers today, and Snap's network is meant to carry EEG home testing into primary care, telehealth, psychiatry and cardiology from 2027.
Alternatives to Beacon Biosignals
Other products that do the same kind of work as Beacon Biosignals, and what each one does.
Point of care EEG company (NASDAQ: CBLL) whose headband and recorder can be placed in minutes in emergency departments and ICUs where conventional EEG and neurology reading are not immediately available.
Rare disease genomic diagnosis company (NASDAQ: WGS) in Gaithersburg, Maryland, running exome and genome sequencing in its own accredited laboratory and interpreting it with automation, machine learning and clinical scientists over GeneDx Infinity, its dataset of prior cases.
AccurKardia makes AccurECG, cloud based software for automated interpretation of ambulatory ECG recordings, sold to cardiac monitoring companies, device manufacturers, hospitals and independent diagnostic testing facilities.
Respiratory diagnostics company developing Sylvee, a chest worn wearable that projects low frequency sound into the lungs and analyzes the returning resonance with machine learning to measure lung volumes, trapped air, respiratory rate and breathing sounds, positioned for early COPD…
Sibel Health makes soft, flexible, wireless sensors that stick to skin and monitor vital signs without cables.
Waiv sells AI tests that read routine H&E slides, for pathology laboratories and oncology teams in Europe, and biomarker services for drug developers.
Pricing
Vendor-published figures are labeled as such. Figures labeled “Estimated” are derived from third-party sources and have not been confirmed by the vendor.
| Entry Price | Pricing Basis | BAA Tier | Implementation | Source |
|---|---|---|---|---|
|
Contact Beacon for pricing
|
Beacon has separate inquiry routes for home sleep testing and life sciences customers. SleepView Direct comes in Gold and Silver plans bundling the monitor, portal access, shipping and disposables. Hardware, trial services, analytics and the SleepView plans have no published price or billing unit. | The service has a clinical data privacy policy. No business associate agreement position or tier is stated. | The clinical study service offers device provisioning, setup, site training and data quality monitoring, with any separate charges set in the study contract. | Vendor Published |
The headband is sold for clinical, study and academic use and not to individual consumers. Beacon offers CPT coding and billing support to SleepView providers, and Snap bills insurers for its own testing as an independent diagnostic testing facility.